Navigation Links
Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono
Date:2/15/2012

LONDON, February 15, 2012 /PRNewswire/ --

Senior representatives from leading pharmaceutical companies including Roche Diagnostics, Lonza, Abbott, F. Hoffman-La-Roche LTD and Novartis MIT will meet at the Pharma Qbd Forum in Berlin, Germany on 24th-25th April 2012 to share their expert knowledge on how Quality by Design can be implemented in pharmaceutical development.

One of the main points of discussion will be the findings of the Merck Serono case study and how the lessons learned from this FDA Pilot Programme can shape the way for QbD projects in Europe and abroad. This session will be led by Pascal Valax, Group Head, Biotech Process Sciences, Merck Serono SA.

Speakers include:

  • Dr. John R Donaubauer, Director, Scientific Affairs Development Sciences Process R&D - Abbott
  • Dr.Richard Lakerveld, Associate - Novartis-MIT Center for Continuous Manufacturing
  • Serj Vartanian, Head of Global Quality Systems MBB - Baxter Healthcare Corporation
  • Dr. Gawayne Mahboubian-Jones, Program head - Excellence in Science and Design - Philip Morris International
  • Dr.Paul Stonestreet, Global Drug Substance Project Co-ordinator, Small Molecule Technical Development - F.Hoffman-La-Roche Ltd
  • Dr. Dirk Pamperin, VP R&D - Synthon Pharmaceuticals
  • Dr. Alessandro Butte, Head of DSP - Lonza
  • Sarah Mercier, Scientist USP - Crucell Holland BV
  • Dr. John Crowley, Head of Cell Culture Development - Lonza Biologics
  • Dr. Andreas Schneider, Vice President Life Science Alliances - Roche Diagnostics
  • Prof. Gary Montague, Professor of Bioprocess Control - Newcastle University
  • Dr. Mel Koch, Executive Director - CPAC Centre for Process and Analytical Control (University of Washington)
  • Prof. Mathieu Streefland, Professor Bioprocess Engineering - Wageningen University
  • Prof. Jose Cardoso de Menezes, Department of BioEngineering - Institute of Biotechnology & Bioengineering

Conference topics include:

  • Building quality earlier in the process
  • Improving process understanding
  • Successfully defining criticality
  • Defining continuous verification and the expanded change protocol
  • Lifecycle strategies for biopharmaceutical QbD
  • Implementing continuous manufacturing with QbD to reduce production timelines
  • Translating established development practice into QbD

To view the complete programme, speakers and topics visit http://www.pharmaqbdforum.com

For all press enquiries, email sarah.brzezicki@wtgevents.com or telephone +44(0)207-202-7727.



'/>"/>
SOURCE World Trade Group Conferences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amerigen Pharmaceuticals and VIWA Pharmaceutical Company Today Jointly Announce the Signing of a Memorandum of Understanding (MOU) Setting Out Their Intention to Establish a Joint Venture to Develop and Register a Range of Branded Generic Medicines
2. HIFU All Hype? Understanding This Non-FDA-Approved Prostate Cancer Treatment
3. Team AFib™ Unites Patient Advocacy Organizations to Elevate Understanding of Atrial Fibrillation and Stroke
4. Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
5. American Pain Foundation Launches New Educational Campaign, "Explain Your Pain," to Help Hispanic Americans Better Understand Chronic Pain and Pain Management
6. FDA Examines Ways to Improve Consumer Understanding of Prescription Drug Ads
7. Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits
8. Ground Breaking Findings on Understanding Cancer Published in the Current Issue of Science
9. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
10. Information-Motivation-Behavioral Skills Analysis Advances Understanding of Barriers to Self-Monitoring of Blood Glucose
11. Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 10, 2016 Intouch Solutions, a leading marketing ... industry-wide trend regarding the evolution of digital sales ... efficiently deliver compelling sales presentations via tablets. After ... in 2015, Intouch uncovered that while most pharmaceutical ... DSAs, many are not using them effectively during ...
(Date:2/10/2016)... Feb. 9, 2016 On Tuesday, ... (FDA) met with its Arthritis Advisory Committee ... of Johnson & Johnson,s Remicade and most ... in the U.S. The Biologics Prescribers Collaborative ... - Alliance for Patient Access, American Association ...
(Date:2/10/2016)... , February 10, 2016 The campaign aims ... 5 years reach the milestone of their 5 th ... ensure 2,50,532 children between the ages of 2 - ...   --> The campaign aims to ... years reach the milestone of their 5 th birthday   ...
Breaking Medicine Technology:
(Date:2/10/2016)... Angeles, CA (PRWEB) , ... February 10, 2016 ... ... Programming (NLP) practitioner, is known locally for a series of therapeutic sessions to ... in-the-moment in their characters and in their lives. The series, known as “Mindfulness ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... master charity program created to assist the local community. Pledging to select a ... and nonprofit organizations in the area. Their goal is to bring community awareness ...
(Date:2/10/2016)... ... ... Ongoing news of the ravages of traumatic brain injury (TBI) among former ... takes a closer look at cases of TBI being managed by their members. The ... the aging population, and identifies the challenges associated with their care. , During the ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a ... network of laboratory service centers across the country. Launched in April of 2015, Apifiny ... detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care ...
Breaking Medicine News(10 mins):